Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIOLA: Nivolumab for malignant mesothelioma from non-pleural origin
jRCT2051200062Phase 2Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in mesothelioma, peritoneal mesothelioma and pericardial mesothelioma, sponsored by Ono Pharmaceutical. Primary endpoint: Tumor shrinkage (objective response rate, central review). Started Oct 2020; status: active, not recruiting.
02
Drugs
03
Conditions
mesotheliomaperitoneal mesotheliomapericardial mesothelioma
Beyond the preview
Go deeper on jRCT2051200062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200062.